Most Read Articles
Christina Lau, 7 months ago

Obinutuzumab reduces the risk of disease progression by about one-third in patients with advanced follicular lymphoma (FL) compared with rituximab, interim results of the phase III GALLIUM study have shown.

Christina Lau, 2 years ago
Family physicians should be involved in the provision of palliative care, particularly in the patient-desired community setting, said experts at the 21st Hong Kong International Cancer Congress.
2 years ago
Catecholamines may regulate serum HDL cholesterol level, abdominal visceral and subcutaneous fat mass in men with pheochromocytoma, based on a cross-sectional and longitudinal follow-up study.
Naomi Adam, 2 years ago
Colorectal cancer is one of the leading cancers worldwide and one of the most difficult to treat because patients often present in later, metastatic stages of disease. Preventing blood vessel growth is a popular therapeutic strategy to help reduce the proliferation of cancerous tissue. Aflibercept (Zaltrap®, Sanofi) is a monoclonal antibody treatment that targets the cell signalling pathways of angiogenesis to prevent blood vessel growth in malignancies.

Studies show benefits of skin cancer screening, but with very low evidence

6 months ago

Skin cancer screening appears to offer benefits based on large ecological studies, a cohort study, a case-control study and a survey, but the evidence level of these reports is very low.

Investigators searched Medline and Embase for research papers published in English or German between 1 January 2005 and 4 February 2015 to update evidence on the impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence, mortality, stage-specific incidence and interval cancers after negative screening.

Study selection, data extraction and critical appraisal were done by two independent reviewers. The results were described in a narrative synthesis. The systematic review included 15 articles from the 2,066 records identified in databases and 10 records found by manual search.

The incidence of in situ and invasive skin cancer rose with the implementation of skin cancer screening based on evidence gathered. Also, researchers found increasing rates of thin and decreasing rates of thick melanoma.

The incidence of invasive melanoma decreased after cessation of screening.

A German study showed a significant decrease in melanoma mortality, while two other reports observed fewer deaths than expected. There was no study on interval cancers identified.

The systematic review had certain weaknesses, including publication bias and the inherent limitation of the studies included due to their ecological design, according to researchers.

Wernli and colleagues presented in a report that, on a population level, no clear statement could be made regarding the benefit of skin cancer screening for melanoma mortality and all-cause mortality or association with thinner lesions due to limited evidence. [Wernli KJ, et al, AHRQ 2016 Report No. 14-05210-EF-1]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Christina Lau, 7 months ago

Obinutuzumab reduces the risk of disease progression by about one-third in patients with advanced follicular lymphoma (FL) compared with rituximab, interim results of the phase III GALLIUM study have shown.

Christina Lau, 2 years ago
Family physicians should be involved in the provision of palliative care, particularly in the patient-desired community setting, said experts at the 21st Hong Kong International Cancer Congress.
2 years ago
Catecholamines may regulate serum HDL cholesterol level, abdominal visceral and subcutaneous fat mass in men with pheochromocytoma, based on a cross-sectional and longitudinal follow-up study.
Naomi Adam, 2 years ago
Colorectal cancer is one of the leading cancers worldwide and one of the most difficult to treat because patients often present in later, metastatic stages of disease. Preventing blood vessel growth is a popular therapeutic strategy to help reduce the proliferation of cancerous tissue. Aflibercept (Zaltrap®, Sanofi) is a monoclonal antibody treatment that targets the cell signalling pathways of angiogenesis to prevent blood vessel growth in malignancies.